Background Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an
obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens …

Abstract Development of new drugs to treat drug-resistant tuberculosis is most important in
the fight against the global spread of this contagious and potentially deadly infectious …

A full understanding of the pharmacokinetic (PK) behavior of each anti‐TB drug and drug
combinations is essential to determine the optimum dose/dosing regimen for a specific …

Objectives To develop physiologically based pharmacokinetic (PBPK) models for widely
used anti-TB drugs, namely rifampicin, pyrazinamide, isoniazid, ethambutol and …

Objective To evaluate the efficacy and safety of bedaquiline (BDQ) in patients with drug
resistant pulmonary tuberculosis (DR-PTB) and to provide guidance for clinical rational and …

Background Identification of pharmacodynamic interactions is not reasonable to carry out in
a clinical setting for many reasons. The aim of this work was to develop a model-informed …

The pharmacokinetics (PK) of a drug is commonly explained as 'what the body does to the
drug'and is typically described in terms of drug disposition—that is: absorption, distribution …

Background: In 2014, an estimated 1.8 million people died from Mycobacterium tuberculosis
(MTB); moreover, 680,000 people developed multidrug-resistant TB (MDRTB). Methods …

The relationships between antituberculosis drug exposure and treatment effects on humans
receiving multidrug therapy are complex and nonlinear. In patients on treatment, an analysis …

Introduction: Despite efforts to the contrary, tuberculosis remains one of the leading causes
of death in the world. The appearance of multidrug-resistant (MDR) and extensively drug …